Polychemotherapy for early breast cancer: An overview of the randomised trials

The Lancet

Volumn 352, Issue 9132, 1998, Pages 930-942

  Abe, O ^a   Abe, R ^a   Enomoto, K ^a   Kikuchi, K ^a   Koyama, H ^a   Nomura, Y ^a,bj   Sakai, K ^a   Sugimachi, K ^a   Tominaga, T ^a   Uchino, J ^a   Yoshida, M ^a   Benraadt, J ^b   van de Velde, A O ^b   van Dongen, J A ^b   Vermorken, J B ^b   Giokas, G ^c   Lissaios, B ^c   Harvey, V J ^d   Holdaway, T M ^d   Kay, R G ^d   Mason, B H ^d   Coates, A ^e   Forbes, J F ^e   Focan, C ^f   Lobelle, J P ^f   Peek, U ^g   Oates, G D ^h   Powell, J ^h   Durand, M ⁱ   Mauriac, L ⁱ   Bartholomeus, S ^j   Piccart, M J ^j   Gelman, R S ^k   Henderson, I C ^k   Shapiro, C L ^k   Hancock, A K ^l   Masood, M B ^l   Parker, D ^l   Price, J J ^l   Jackson, S ^m   Ragaz, J ^m   Delozier, T ⁿ   Mace Lesec'h, J ⁿ   Haybittle, J L ^o   Berry, D ^p   Broadwater, G ^p   Cirrincione, C ^p   Muss, H ^p   Norton, L ^p,br   Baum, M ^q,bz   Houghton, J ^q   Riley, D ^q   Dent, D M ^r   Gudgeon, C A ^r   Hacking, A ^r,dd   Gordon, N H ^s   Davis, H L ^t   Romestaing, P ^u   Lehingue, Y ^u   Owen, J R ^v   Meier, P ^w   Howell, A ^x   Ribeiro, G C ^x   Swindell, R ^x,cc   Albano, J ^y   de Oliveira, C F ^y   Gervasio, H ^y   Gordilho, J ^y   Carstensen, B ^z   Palshof, T ^z   Johansen, H ^aa   Korzeniowski, S ^ab   Skolyszewski, J ^ab   Portnoj, S M ^ac   Andersen, K W ^ad   Axelsson, C K ^ad   Blichert Toft, M ^ad   Mouridsen, H T ^ad   Overgaard, M ^ad   Rose, C ^ad   Corcoran, N ^ae   Trampisch, H J ^af   Comis, R L ^ag   Davidson, N E ^ag   Gray, R ^ag,co   Robert, N ^ag   Tormey, D C ^ag   Wood, W ^ag   Chetty, U ^ah   Forrest, P ^ah   Jack, W ^ah   Rossbach, J ^ai   Sylvester, R J ^aj   van de Velde, C J H ^aj,bk   Cunningham, M P ^ak   Bonneterre, J ^al   Fumoleau, P ^al   Namer, M ^al   Bastert, G ^am   Rauschecker, H ^am   Sauer, R ^am   Sauerbrei, W ^am   Schauer, A ^am   Schumacher, M ^am   de Schryver, A ^an   Belfiglio, M ^ao   Mari, E ^ao   Nicolucci, A ^ao   Scorpiglione, N ^ao   Yosef, H M A ^ap   McArdle, C S ^aq   Smith, D C ^aq   Lara, P C ^ar   Boccardo, F ^as   Rubagotti, A ^as   Erazo, A ^at   Medina, J Y ^at   Izuo, M ^au   Morishita, Y ^au   Bentley, A ^av   Doran, Z ^av   Fentiman, I S ^av   Hayward, J L ^av   Rubens, R D ^av   Kaufmann, M ^aw,ax   Jonat, W ^aw   Scheurlen, H ^ax   von Fournier, D ^ax   Fountzilas, G ^ay   Klefstrom, P ^az   Blomqvist, C ^ba   Cuzick, J ^q   Margreiter, R ^bb   Castiglione, M ^bc,dn   Cavalli, F ^bc   Collins, J ^bc   Forbes, J ^bc   Gelber, R D ^bc   Goldhirsch, A ^bc,dn   Lindtner, J ^bc   Price, K N ^bc   Rudenstam, C M ^bc   Senn, H J ^bc,dn   Bliss, J M ^bd   Chilvers, C E D ^bd   Coombes, R C ^bd   Marty, M ^bd   Borovik, R ^be   Brufman, G ^be   Hayat, H ^be   Robinson, E ^be   Wigler, N ^be   Pannuti, F ^bf   Takashima, S ^bg   Yasutomi, T ^bg   Sonoo, H ^bh   Yamashita, J ^bi   Ogawa, M ^bi   Welvaart, K ^bk   Hupperets, P S G J ^bl   Bonte, J ^bm   Tengrup, I ^bn   Tennvall Nittby, L ^bn   Martin, P ^bo   Romain, S ^bo   Ingle, J N ^bp,ca   Suman, V J ^bp,ca   Buzdar, A U ^bq   Smith, T ^bq   Hakes, T ^br   Wittes, R ^br   de la Huerta, R ^bs   Sainz, M G ^bs   Bonadonna, G ^bt   Del Vecchio, M ^bt   Valagussa, P ^bt   Veronesi, U ^bt   Dubois, J B ^bu   Bianco, A R ^bv   Lippman, M E ^bw   Pierce, L J ^bw   Simon, R ^bw   Steinberg, S M ^bw   Myles, J D ^bx   Pater, J L ^bx   Pritchard, K I ^bx,dq,dr   Anderson, S ^by   Brown, A ^by   Bryant, J ^by   Costantino, J ^by   Dignam, J ^by   Fisher, B ^by   Redmond, C ^by   Wieand, S ^by   Wolmark, N ^by   Jackson, I M ^bz   Palmer, M K ^bz   Bengtsson, N O ^cb   Larsson, L G ^cb   Lythgoe, J P ^cc   Kissin, M ^cd   Hannisdal, E ^ce   Varhaug, J E ^ce   Nissen Meyer, R ^cf,df   Blamey, R W ^cg   Mitchell, A K ^cg   Robertson, J F R ^cg   Ueo, H ^ch   Mathe, G ^ci   Misset, J L ^ci   Abu Zahra, H T ^cj   Clarke, E A ^cj   McLaughlin, J R ^cj   Clark, R M ^ck   Levine, M ^ck   Morimoto, K ^cl   Sawa, K ^cm   Takatsuka, Y ^cm   Gundersen, S ^cf   Hauer Jensen, M ^cf   Host, H ^cf,dd   Crossley, E ^cn   Harris, A ^cn   Beighton, A ^co   Clarke, M ^co   Collins, R ^co   Davies, C ^co   Evans, V ^co   Godwin, J ^co   Greaves, E ^co   Harwood, C ^co   Jackson, D ^co   James, S ^co   Lau, E ^co   Mead, G ^co   Naughten, A ^co   Peto, R ^co   Tooth, A ^co   Rambert, P ^cp   Asselain, B ^cq   Salmon, R J ^cq   Vilcoq, J R ^cq   Arriagada, R ^cr   Hill, C ^cr   Laplanche, A ^cr   Le, M G ^cr   Spielmann, M ^cr   Cocconi, G ^cs   Di Blasio, B ^cs   Catalano, R ^ct   Creech, R H ^ct   Brockschmidt, J ^cu   Cooper, M R ^cu   Andrysek, O ^cv   Barkmanova, J ^cv   Falkson, C I ^cw   Abraham, M ^cx   Klijn, J G M ^cy   Treurniet Donker, A D ^cy   van Putten, W L J ^cy   Easton, D ^cz   Powles, T J ^cz   Gazet, J C ^da   Semiglazov, V ^db   Deshpande, N ^dc   Martino, L Di ^dc   Douglas, P ^dd   Lindtner, A ^dd   Notter, G ^dd   Bryant, A J S ^de   Ewing, G H ^de   Krushen Kosloski, J L ^de   George, W D ^dg   Gould, A ^dg   Stewart, H J ^dg   Stroner, P ^dg   Moller, T R ^dh   Ryden, S ^dh   Carstensen, J ^di   Hatschek, T ^di   Soderberg, M ^di   Carpenter, J T ^dj   Albain, K ^dk   Crowley, J ^dk   Green, S ^dk   Martino, S ^dk   Osborne, C K ^dk   Ravdin, P M ^dk   Rutqvist, L E ^dl   Wallgren, A ^dl   Holm, L E ^dm   Thurlimann, B ^dn   Brenner, H ^do   Hercbergs, A ^do   Yoshimoto, M ^dp   Deboer, G ^dq   Paterson, A H G ^dq   Meakin, J W ^dr   Panzarella, T ^dr   Naja, A ^ds   Bahi, J ^dt   Reid, M ^du   Spittle, M ^du   Senanayake, F ^dv   Bergh, J ^dw   Holmberg, L ^dw   Sevelda, P ^dx   Zielinsky, C C ^dx   Gnant, M ^dx   Jakesz, R ^dx   Buchanan, R B ^dy   Cross, M ^dy   Dunn, J A ^dz   Gillespie, W M ^dz   Kelly, K ^dz   Morrison, J M ^dz   Litton, A ^ea   Chlebowski, R T ^eb   Bezwoda, W R ^ec   Caffier, H ^ed   more..

^a ACETBC   (Japan)

^b Integraal Kankercentrum   (Netherlands)

^c METAXA CANCER HOSPITAL   (Greece)

^d Auckland Breast Cancer Study Group   (New Zealand)

^e Australian New Zealand Breast Cancer Trials Group ^*  (Australia)

^f Belgian Adjuvant Breast Cancer Project   (Belgium)

^g Berlin Brandenburgische Akademie der Wissenschaften   (Germany)

^h Birmingham General Hospital   (United Kingdom)

ⁱ INSTITUT BERGONIÉ   (France)

^j JULES BORDET INSTITUTE   (Belgium)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l BRADFORD ROYAL INFIRMARY   (United Kingdom)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ Caen Centre Regional Francois Baclesse   (France)

^o ADDENBROOKE S HOSPITAL   (United Kingdom)

^p Cancer and Leukemia Group B   (United States)

^q IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^r UNIVERSITY OF CAPE TOWN   (South Africa)

^s CASE WESTERN RESERVE UNIVERSITY   (United States)

^t Central Oncology Group   (United States)

^u CENTRE LÉON BÉRARD   (France)

^v CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^w UNIVERSITY OF CHICAGO   (United States)

^x CHRISTIE HOSPITAL   (United Kingdom)

^y Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^z Danish Cancer Registry   (Denmark)

^aa Back Center of Copenhagen   (Denmark)

^ab Cracow Institute of Oncology   (Poland)

^ac CRCRAMS   (Russian Federation)

^ad Danish Breast Cancer Cooperative Group   (Denmark)

^ae ST LUKE S HOSPITAL   (Ireland)

^af HEINRICH HEINE UNIVERSITY   (Germany)

^ag Eastern Cooperative Oncology Group   (United States)

^ah Edinburgh Breast Unit   (United Kingdom)

^ai Diakonie Klinikum Hamburg   (Germany)

^aj EORTC DATA CENTER   (Belgium)

^ak EVANSTON HOSPITAL   (United States)

^al GFEA   (France)

^am GBSG   (Germany)

^an GHENT UNIVERSITY HOSPITAL   (Belgium)

^ao GIVIO Interdisciplinary Group for Cancer Care Evaluation   (Italy)

^ap BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^aq VICTORIA INFIRMARY   (United Kingdom)

^ar UNIVERSITY OF GRANADA   (Spain)

^as Gruppo Ricerca Ormono Chemio Terapia Adiuvante (GROCTA)   (Italy)

^at Guadalajara Hospital de 20 Noviembre   (Mexico)

^au GUNMA UNIVERSITY   (Japan)

^av GUY S HOSPITAL   (United Kingdom)

^aw Gynecological Adjuvant Breast Group   (Germany)

^ax UNIVERSITY OF HEIDELBERG   (Germany)

^ay Hellenic Cooperative Oncology Group   (Greece)

^az Helsinki Deaconess Medical Centre   (Finland)

^ba UNIVERSITY OF HELSINKI   (Finland)

^bb UNIVERSITY OF INNSBRUCK   (Austria)

^bc International Breast Cancer Study Group (Ludwig)   (Switzerland)

^bd CHARING CROSS HOSPITAL   (United Kingdom)

^be Israel NSABC   (Israel)

^bf Italian Cooperative Chemo Radio Surgical Group   (Italy)

^bg Japanese National Hospitals Group Breast Cancer Study Group   (Japan)

^bh KAWASAKI MEDICAL SCHOOL   (Japan)

^bi KUMAMOTO UNIVERSITY   (Japan)

^bj National Hospital Kyushu Cancer Center   (Japan)

^bk LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^bl Breast Cancer Study Group of the Comprehensive Cancer Centre   (Netherlands)

^bm Louvain Academisch Ziekenhuis St Rafael   (Belgium)

^bn LUND UNIVERSITY   (Sweden)

^bo Marseille Laboratoire de Cancerologie Biologique APM   (France)

^bp MAYO CLINIC   (United States)

^bq UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^br MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bs Mexican National Medical Centre   (Mexico)

^bt NATIONAL CANCER INSTITUTE   (Italy)

^bu Montpellier Centre Paul Lamarque   (France)

^bv UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^bw NATIONAL CANCER INSTITUTE   (United States)

^bx Queen's Cancer Research Institute   (Canada)

^by NSABP Foundation Inc   (United States)

^bz Nolvadex Adjuvant Trial Organisation   (United Kingdom)

^ca North Central Cancer Treatment Group Rochester   (United States)

^cb North Sweden Breast Cancer Group   (Sweden)

^cc North Western British Surgeons   (United Kingdom)

^cd NORTHWICK PARK HOSPITAL   (United Kingdom)

^ce Norwegian Breast Cancer Group   (Norway)

^cf OSLO UNIVERSITY HOSPITAL   (Norway)

^cg NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^ch OITA PREFECTURAL HOSPITAL   (Japan)

^ci Oncofrance   (France)

^cj Ontario Cancer Treatm Res Found   (Canada)

^ck PEDIATRIC ONCOLOGY GROUP OF ONTARIO   (Canada)

^cl Osaka Prefecture University   (Japan)

^cm OSAKA NATIONAL HOSPITAL   (Japan)

^cn CHURCHILL HOSPITAL   (United Kingdom)

^co CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^cp CENTRE RENÉ HUGUENIN   (France)

^cq INSTITUT CURIE   (France)

^cr INSTITUT GUSTAVE ROUSSY   (France)

^cs Parma Hospital   (Italy)

^ct FOX CHASE CANCER CENTER   (United States)

^cu Piedmont Oncology Association   (United States)

^cv CHARLES UNIVERSITY   (Czech Republic)

^cw UNIVERSITY OF PRETORIA   (South Africa)

^cx Medical School of Ciudad de Rosario   (Argentina)

^cy ERASMUS MEDICAL CENTER   (Netherlands)

^cz ROYAL MARSDEN HOSPITAL   (United Kingdom)

^da ST GEORGE S HOSPITAL   (United Kingdom)

^db N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^dc Sardinia Oncology Hospital A Businico   (Italy)

^dd SASIB International Trialists   (South Africa)

^de SASKATCHEWAN CANCER AGENCY   (Canada)

^df Scandinavian Adjuvant Chemotherapy Study Group   (Norway)

^dg Scottish Cancer Therapy Network   (United Kingdom)

^dh South Swedish Breast Cancer Group   (Sweden)

^di South East Sweden Breast Cancer Group   (Sweden)

^dj Southeastern Cancer Study Group and Alabama Breast Cancer Project   (United States)

^dk South West Oncology Group   (United States)

^dl Stockholm Breast Cancer Study Group   (Sweden)

^dm KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^dn SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^do TEL AVIV UNIVERSITY   (Israel)

^dp CANCER INSTITUTE HOSPITAL   (Japan)

^dq Toronto Edmonton Breast Cancer Study Group   (Canada)

^dr PRINCESS MARGARET HOSPITAL   (Canada)

^ds INSTITUT CLAUDIUS REGAUD   (France)

^dt SALAH AZAIEZ INSTITUTE   (Tunisia)

^du UK Multicentre Cancer Chemotherapy Study Group   (United Kingdom)

^dv UK/Asia Collaborative Breast Cancer Group   (United Kingdom)

^dw Cancer Center Uppsala Örebro   (Sweden)

^dx UNIVERSITY OF VIENNA   (Austria)

^dy Wessex Radiotherapy Centre   (United Kingdom)

^dz West Midlands Oncology Association   (United Kingdom)

^ea West of Scotland Breast Trial Group   (United Kingdom)

^eb Western Cancer Study Group   (United States)

^ec UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ed UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY CANCER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032547564     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03301-7     Document Type: Article

References (18)

1. 1 Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319: 1681-92.
2. 2 Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, vol 1: worldwide evidence 1985-1990. Oxford: Oxford University Press, 1990.
3. 3 Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
4. 4 Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials. N Engl J Med 1995; 333: 1444-55.
5. 5 Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-96.
6. 6 Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
7. 7 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612 and 1977; 35: 1-39.
8. 7 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34: 585-612 and 1977; 35: 1-39.
9. 8 Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82.
10. 9 Albain K, Green S, Osborne K, et al, for SWOG, ECOG, CALGB, NCCTG and NCI-Canada. Tamoxifen versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential tamoxifen in postmenopausal, receptor (+), node (+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc ASCO 1997; 16: 450 (abstr).
11. 10 Clahsen PC, van de Velde CJ, Goldhirsch A, et al. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer. J Clin Oncol 1997; 15: 2526-35.
12. 11 Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. In: Weatherall D, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine, vol 1. Oxford: Oxford University Press, 1996: 21-32.
13. 12 Ragaz J, Jackson S, Nilson K, et al. Randomized study of locoregional radiotherapy and ovarian ablation in premenopausal patients with breast cancer treated with adjuvant chemotherapy. Proc Am Soc Clin Oncol 1988; 7: 12 (abstr).
14. 13 Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985; 3: 1059-67.
15. 14 Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978; 298: 1223-28.
16. 15 Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 1980; 42: 635-44.
17. 16 Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18.
18. 17 Pritchard KI, Paterson AMG, Fine S, et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15: 2302-11.